Results 281 to 290 of about 1,643,238 (355)

Septic pulmonary embolism arising from a small temporal boil in a patient with diabetes mellitus type 2: A rare case report. [PDF]

Clin Case Rep
Yildirim S, Yigit Y, Alkahlout BH, Mohamed EH, Azad AM.   +4 more
europepmc   +1 more source

Serum and urinary levels of MIF, CD74, DDT and CXCR4 among patients with type 1 diabetes mellitus, type 2 diabetes and healthy individuals: Implications for further research. [PDF]

Metabol Open
Mangano K, Diamantopoulos A, Vallianou NG, Stratigou T, Panagopoulos F, Kounatidis D, Dalamaga M, Fagone P, Nicoletti F.   +8 more
europepmc   +1 more source

Electrochemical Breath Sensors in Medical Diagnostics: Emerging Trends and Future Directions

ChemElectroChem, EarlyView.
Electrochemical breath sensors (EBSs) are emerging as powerful tools for noninvasive health diagnostics. This perspective highlights recent advances in EBS technologies, explores their potential in mental health monitoring via gut‐derived volatile organic compounds, and outlines future directions for achieving sensitive, selective, and clinically ...
Natalie E. Strom, Courtney J. Weber, Olja Simoska   +2 more
wiley   +1 more source

Biaryl Phosphate‐Based Inhibitors of the Transcription Factor STAT4

ChemMedChem, EarlyView.
The transcription factor signal transducer and activator of transcription (STAT)4 is a potential target for autoimmune diseases. p‐Biphenyl phosphate is reported as an inhibitor of the STAT4 Src homology 2 domain and it is developed to the phosphonate Stafori‐1.
Nadiya Brovchenko, Anne Maria Oelsch, Christoph Protzel, Thorsten Berg   +3 more
wiley   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Type-2 Diabetes Mellitus: risk factors in a school in the health field

, 2000
Maria Carolina Alves Ortiz, María Lúcia Zanetti   +1 more
openalex  

A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide

Clinical Pharmacology &Therapeutics, EarlyView.
About half of the world's population is living with overweight or obesity. Tirzepatide is an approved treatment for chronic weight management. We sought to characterize the exposure–response relationship for weight reduction in patients with overweight or obesity and quantify the associated changes in body composition.
Emmanuel Chigutsa, Lucy Her, Xiaosu Ma, Shweta Urva, Karen Schneck   +4 more
wiley   +1 more source

Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis. [PDF]

PLoS One
Dimnjaković J, Buble T, Ivanko P, Poljičanin T, Karanović Štambuk S, Brborović H, Brborović O.   +6 more
europepmc   +1 more source

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT‐ACS Emulation Using National Health Insurance Claims Data

Clinical Pharmacology &Therapeutics, EarlyView.
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang, Yee‐Jen Wu, Fang‐Ju Lin, Chien‐Chih Wu, Hsin‐Yi Huang, Chi‐Chuan Wang, Xiaojuan Li   +6 more
wiley   +1 more source

Bringing Trial Activities to Participants—The Trials@Home RADIAL Proof‐of‐Concept Trial Investigating Decentralization of Trials

Clinical Pharmacology &Therapeutics, EarlyView.
The interest in trials in which activities are being moved to the participants' direct environment, that is, decentralized, has increased in recent years, but limited research has been conducted into the feasibility and acceptability of such approaches.
Mira G.P. Zuidgeest, Megan Heath, Bart Lagerwaard, Danny R. van Weelij, Linda Rutgrink, Sten Hanke, Tea Vedenkannas, Taru Kosonen, Stefania Collamati, Jaime Fons‐Martínez, Duco Veen, Helga Gardarsdottir, Isla S. Mackenzie, Sabine Dupont, Diederick E. Grobbee, on behalf of the Trials@Home consortium   +15 more
wiley   +1 more source